Revolution Medicines, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $0.0 | $0.0 | $<0.1 | $<0.1 | $<0.1 |
| Operating income | -$1.2 | -$0.7 | -$0.5 | -$0.3 | -$0.2 |
| Net income | -$1.1 | -$0.6 | -$0.4 | -$0.2 | -$0.2 |
| Cash Flow Statement | |||||
| Free cash flow | -$0.9 | -$0.6 | -$0.4 | -$0.2 | -$0.2 |
| Dividends | $0.0 | $0.0 | $0.0 | $0.0 | $0.0 |
Shares outstanding 214.3M · Free float 92.7%
Annual filing data through FY ended December 31, 2025; float as of October 1, 2026.